Cabergoline vs Bromocriptine for Hyperprolactinemia

Inclusion Criteria: * Women aged 18 to 45 at the time of signing the ICF; * Clinically diagnosed hyperprolactinemia, with or without pituitary PRL tumor; * Agree to and abide by the adoption of effective contraceptive measures during the study period (from signing the ICF to 4 weeks after the last administration of the investigational drug); * voluntarily signed the ICF, could understand and abide by the requirements of this research protocol, and were followed up regularly and on time. Exclusion Criteria: * Women who are pregnant or breastfeeding; * Those who have previously received carbergoline treatment or radiotherapy, or have a history of allergy to ergol preparations or their derivatives; * The presence of other types or mixed pituitary tumors； * hyperprolactinemia syndrome caused by hypothalamic or other intracranial lesions； * hyperprolactinemia syndrome caused by other systemic diseases; * Laboratory tests during the screening period meet any of the following conditions: 1. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 times ULN, or total bilirubin (TBIL) \> 1.5 times ULN, or serum creatinine (Cr) or UREA (UREA)/urea nitrogen (BUN) \> 2 times ULN; 2. Those who are positive for hepatitis B surface antigen, hepatitis C antibody, HIV antibody and Treponema pallidum antibody; 3. Hyperprolactinemia: Screening tests show that the PRL recovery rate is less than 40%; * Those who have received ovulation-inducing agents, drugs that may cause an increase in PRL or other prohibited combination drugs within 4 weeks prior to screening; * The patients not suitable for participating in this clinical study due to other reasons.